Get the Stockscreener App
7.18
3.46%
0.24
After Hours:
7.16
-0.02
-0.28%
Gyre Therapeutics Inc stock is traded at $7.18, with a volume of 100.53K.
It is up +3.46% in the last 24 hours and down -16.99% over the past month.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$6.94
Open:
$7.11
24h Volume:
100.53K
Relative Volume:
0.98
Market Cap:
$655.63M
Revenue:
$116.59M
Net Income/Loss:
$9.88M
P/E Ratio:
319.11
EPS:
0.0225
Net Cash Flow:
$-2.40M
1W Performance:
+2.43%
1M Performance:
-16.99%
6M Performance:
-1.51%
1Y Performance:
-24.34%
1-Day Range:
$7.10
$7.34
1-Week Range:
$6.58
$7.34
52-Week Range:
$6.11
$11.78
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(858) 567-7770
Address
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.18 | 633.72M | 116.59M | 9.88M | -2.40M | 0.0225 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy |
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Will Gyre Therapeutics Inc stock hit new highs in YEAR2026 Spike Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday - MarketBeat
Gyre Therapeutics Submits NDA for F351 (Hydronidone) to China CDE for Treatment of Chronic Hepatitis B-Induced Liver Fibrosis - Minichart
Gyre Therapeutics Files NDA in China for F351 - TipRanks
Gyre Therapeutics (GYRE) submits China NDA for Hydronidone in CHB liver fibrosis - Stock Titan
EV Market: What are analysts price targets for Gyre Therapeutics Inc2026 Drop Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2%Time to Sell? - MarketBeat
China grants priority review to Gyre’s liver fibrosis drug By Investing.com - Investing.com India
China grants priority review to Gyre’s liver fibrosis drug - Investing.com
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - Bitget
Aug Intraday: Is Gyre Therapeutics Inc currently under institutional pressureTrade Ideas & Weekly Top Gainers Alerts - baoquankhu1.vn
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics, Inc. Announces China?s NMPA Grants Priority Review to the NDA for Hydronidone for CHB-Induced Liver Fibrosis Treatment - marketscreener.com
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions - The Globe and Mail
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results - MarketBeat
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold - MarketBeat
Gyre Therapeutics 2025 10-K: Revenue $116.6M, Net Income Per Share Decline - TradingView
Gyre Therapeutics (NASDAQ: GYRE) grows China fibrosis base, eyes Hydronidone NDAs - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st
Gyre Therapeutics, Inc. (GYRE) Q4 earnings miss estimates - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap DownShould You Sell? - MarketBeat
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics, Inc. Provides Revenues Outlook for 2026 - marketscreener.com
GYRE | Gyre Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics (NASDAQ: GYRE) details F351, ETUARY and CG001419 outlook at investor conference - Stock Titan
Gyre Therapeutics reports fourth quarter and full year 2025 financial results - marketscreener.com
(GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Revenue $37.2M, vs. FactSet Est of $35.4M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS - marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports 10% Revenue Growth in Full-Year 2025 and Announces Acquisition of Cullgen - Quiver Quantitative
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Caledonian Record
Biotech Gyre to add $300M degrader drug pipeline in 2026 deal - Stock Titan
Gyre Therapeutics (NASDAQ: GYRE) grows 2025 revenue but guides 2026 decline - Stock Titan
Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Earnings Update: Can Gyre Therapeutics Inc maintain its current growth rateJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):